1.66
+0(+0.00%)
Currency In USD
| Previous Close | 1.66 |
| Open | 1.66 |
| Day High | 1.68 |
| Day Low | 1.62 |
| 52-Week High | 8.83 |
| 52-Week Low | 1.57 |
| Volume | 1.02M |
| Average Volume | 2.76M |
| Market Cap | 189.06M |
| PE | -1.01 |
| EPS | -1.64 |
| Moving Average 50 Days | 2.5 |
| Moving Average 200 Days | 3.9 |
| Change | 0 |
If you invested $1000 in Fate Therapeutics, Inc. (FATE) 10 years ago, it would be worth $296.43 as of December 26, 2024 at a share price of $1.66. Whereas If you bought $1000 worth of Fate Therapeutics, Inc. (FATE) shares 5 years ago, it would be worth $82.67 as of December 26, 2024 at a share price of $1.66.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
GlobeNewswire Inc.
Dec 09, 2024 9:01 PM GMT
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission
Fate Therapeutics Announces Leadership Transition
GlobeNewswire Inc.
Nov 29, 2024 6:05 PM GMT
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate The
Fate Therapeutics to Present at Upcoming December Investor Conferences
GlobeNewswire Inc.
Nov 26, 2024 9:01 PM GMT
SAN DIEGO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies